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The emergence of drug-resistant tuberculosis (TB), particularly multidrug-resistant (MDR) and extensively
drug-resistant (XDR) TB, is a major public health problem. The purpose of this review is to describe the current
status of MDR-TB and factors that increase the risk of this infection. We conducted a systematic review of the
literature on MDR-TB in Ethiopia. Out of 766 articles, 23 were found to meet eligibility criteria and included in
this review. Among the 23 papers, six of them reported high prevalence of MDR-TB in the range of 3.3%-46.3%.
Likewise, two studies reported XDR-TB in the range of 1% - 4.4% in Ethiopia. The most powerful predictor of the
emergence of MDR-TB reported in Ethiopia is previous exposure to anti-TB drug treatment. This review indicated
that MDR-TB in Ethiopia is a serious public health problem that needs to be addressed urgently. Strengthening
early case detection and proper treatment of drug-susceptible TB in accordance with World Health Organization
(WHO) treatment guidelines to ensure adequate treatment success rates is critical. Consequently, efforts have
been made to a rapidly increase MDR-TB diagnosis as well as the number of treatment sites to implement a
directly observed treatment, short-course (DOTS) plus strategy to interrupt transmission of MDR-TB.
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Tuberculosis (TB) remains a major global public health
problem. It causes illness among millions of people each
year and is ranked as the second leading cause of death
from an infectious disease worldwide [1]. Globally around
8.6 million new TB cases in 2012 were reported and 1.3
million die every year as a result of TB [1]. Ethiopia,
having experienced a major increase in the burden of TB,
presents one of the most serious public health challenges.
Ethiopia is highly afflicted by the TB pandemic and is
ranked second after Nigeria in Africa and seventh among
the 22 high TB burden countries worldwide [2].
Multidrug-resistant (MDR) TB has become a major
public health problem and presents new barriers to the
control of TB [1]. Drug-resistant TB is a man-made
problem, largely being the consequence of human error* Correspondence: fantahun.degeneh@gmail.com
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article, unless otherwise stated.as a result of poor supply management and quality of
anti-TB drugs and inadequate or improper treatment,
which is further exacerbated by human immunodeficiency
virus (HIV) [1]. Poor infection control practice has also
been identified as a major contributing factor for the spread
of drug-resistant TB [1]. Nearly half a million cases of
MDR-TB emerge every year, but only 3% of them get treat-
ment globally and 110,000 die annually [3]. The World
Health Organization’s (WHO’s) 2010 Global MDR-TB
report estimated that there were 440,000 MDR-TB cases
[3.6% (95% CI: 3.0-4.4)] and 150,000 deaths due to MDR-
TB worldwide in 2008 [4]. China and India accounted
more than half of the MDR-TB worldwide [4]. According
to a WHO/IUATLD (World Health Organization/Inter-
national Union Against Tuberculosis and Lung Disease)
survey of 20 countries with the highest rates of MDR-TB
among previously treated cases, 14 were in the European
Region [5]. In Africa 69,000 MDR-TB cases were reported
in 2008 [4]. Extensively drug-resistant TB (XDR-TB) has
been reported worldwide and an estimated 9.6% (95% CI:
8.1%-11%) of MDR-TB cases are XDR-TB [1].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ranked 15th with more than 5000 estimated MDR-TB
patients each year [3]. According to the WHO report, the
prevalence of MDR-TB has been 2.8% in newly diagnosed
patients; it is reportedly even higher in patients who have
previously received anti-TB treatment 21% [1,6]. Published
studies on MDR-TB are increasingly available worldwide,
but accurate data on drug-resistant TB in Ethiopia is
limited. Upon this background, this review provides a
comprehensive and up-to-date assessment of the status
of the MDR-TB epidemic in Ethiopia, following up on a
series of reports on anti-TB drug-resistance previously
reported by WHO. Therefore, the purpose of this review
is to describe the current status of MDR-TB in Ethiopia,
the factors that increased the risk of drug resistance and
discuss the importance of our findings for informing TB
control strategies in Ethiopia.
Methods
The literature search strategy in this paper included
searching PubMed/Medline and the Google scholar
database using keywords such as “Tuberculosis” and
“MDR-TB”, “XDR-TB”, “risk factors”, “drug resistance”,
“incidence rate”, and “control”. Each term was searched
separately with the name of the study region. Only English
language papers and WHO websites were included in
the search and the searches were focused on studies of
prevalence, drug resistance, MDR-TB, XDR-TB and major
risk factors associated with drug-resistant TB. Literature
that did not report on a study of MDR and XDR-TB were
excluded. The three authors independently reviewed all
of the studies found and WHO websites. A structured
form for data extraction was used and included such
points as the place where the study was conducted, year
of publication, TB incidence rate, prevalence of any
drug resistance, isoniazid (INH) and rifampicin (RMP)
resistance, MDR- and XDR-TB, risk factor for the incidence
and drug-resistant TB. The frequency of prevalence, drug
resistance of TB and risk factors reported in all the selected
studies were assessed and tallied. In this review we report
the risk factors most commonly reported in the literature.
Meta-analysis was not used to assess risk factors due to
differences in the methodologies used and incomplete
result reporting.
Operational definitions
The following definitions relating to drug resistance
were used [4,7,8]:
– -Drug-resistant TB - TB that is resistant to any
first-line anti-tuberculosis drug.
– -Isoniazed monoresistant TB - TB caused by
strains of M.tuberculosis that are resistant to
only INH.– -Rifampicin monoresistant TB - TB caused by strains
of M.tuberculosis that are resistant to only RMP.
– -MDR-TB – TB caused by strains of M.tuberculosis
that are resistant to at least INH and RMP.
– -XDR-TB - MDR-TB plus resistant to fluoroquinolone
and at least one second-line injectable agent:
amikacin, kanamycin, and/or capreomycin
– -Primary drug resistance - Drug-resistant TB in a
person with no history of TB treatment, implying
they were infected with a resistant TB. This reflects
person-to-person transmission of drug-resistant
TB bacilli.
– -Acquired drug resistance - Drug-resistant TB in a
person with a history of TB treatment. This reflects
drug resistance acquired during TB treatment but




Our electronic search resulted in 766 citations. Out of
766 articles, 604 were excluded after reviewing their
titles, 12 were found to be duplicates, 107 were excluded
because the title and/or abstracts indicated that they did
not report on subjects directly related to our topic and
20 were excluded following full text review. A total of 23
papers were met our eligibility criteria and were included
in the review (Figure 1). Among the 23 papers, six of them
reported high prevalence of MDR-TB in the range of
3.3%-46.3%. Likewise, two studies reported XDR-TB in
the range of 1% - 4.4% in Ethiopia (Table 1). Ethiopia’s TB
case notification, case detection and treatment success
rate are summarized in Figures 2, 3, and 4, respectively.
Trends in the MDR-TB detection rate among all cases
from 2007 to 2012 showed an increase from 130 cases
to 284 cases (Figure 5). Figure 6 presents a summary of
risk factors associated to the occurrence of MDR-TB in
Ethiopia. HIV/AIDS, previous exposure to TB treatment,
exposure to a known MDR-TB case, history of using
poor quality TB drugs, treatment in a poorly-performing
control program, mal-absorption, treatment not directly
observed by a health worker, being male, and failure of
first-line short-course chemotherapy were found to be
associated with increased risk of MDR-TB in Ethiopia.
Previous exposure to anti-TB drug treatment was found
to be the most powerful predictor of MDR-TB incidence
reported, followed by HIV/AIDS, in Ethiopia (Table 2).
Epidemiological evidence of MDR-TB in Ethiopia
The WHO report in 2013 indicated that 450,000 new
cases of MDR-TB and 170,000 deaths due to MDR-TB
occurred globally in 2012. In Africa data on MDR-TB is
scarce. However, between 2007 and 2012, a total of
65,422 MDR-TB cases were reported by 15 countries
A total of 766 articles were
identified




107 were excluded because 
title and/or abstracts 
indicated that they didn’t 
report on directly related to 
our topic
20 were excluded following 
full text review
Figure 1 Flow diagram that shows literature review.
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http://www.aricjournal.com/content/3/1/31[1,9]. South Africa comprises of 87.9% of the African
burden of MDR-TB [1]. The current WHO estimate of
MDR-TB prevalence among all cases in South Africa is
15,419. Likewise, 2336 XDR-TB cases were reported
from five countries [9], of these 97.6% of them were in
South Africa. South Africa remains the country that
reports the highest XDR-TB cases in the world and the
annual notification rate increased from 467 in 2009 to
1596 in 2012 [1]. About 10% of MDR-TB cases reported
in this country were XDR-TB. Genotype studies haveTable 1 Reported drug-resistant TB in Ethiopia, 1994-2012
Author Study time Any drug resistance%
Demissie et al. [12] 1994 15.6
Abate et al. [13] 1998 50
Bruchfed et al. [14] 1996-1997 14
Gebeyehu et al. [15] 2001 19.5
Desta et al. [16] 2004-2005 27.4
Asmamaw et al. [17] 2004-2005 21.4
Wright et al. [18] 2002-2007 26.9
Agonafir et al. [19] 2005-2006 60.8
Hussen et al. [20] 2011 36.3
Yimer et al. [21] 2008 30.1
Abate et al. [22] 2004-2008 72.9
Tessema et al. [23] 2009 15.8
Abebe et al. [24] 2010-2011 18.4
[Internet] [25] 2010-2011 31
Biadglegne et al. [26] 2012 6.7
Esmael et al. [27] 2010-2011 33.5
Ejigu et al. [28] 2005 0.0
Demissie et al. [29] 1998 12.9
Wolde et al. [30] 1986 15.2
NR- not reported.shown that between 63% and 75% of XDR-TB cases
progress through acquisition of resistance [10].
In Ethiopia, the incidence of MDR-TB strains is a con-
tinuing challenge to the TB control program. The first
national surveillance data during the 2003–2005 study
periods reported 1.5% MDR-TB in Ethiopia [11]. Ethiopia
has been one of the highest TB burden countries with
respective incidence and prevalence rates of 247 and 470
cases per 100,000 in 2012 [1]. The value for the estimated
number of TB cases in Ethiopia has varied between 431 inINH% RMP% MDR-TB% XDR-TB%
8.4 1.8 1.2 NR
45 12 12 NR
8.3 2.5 0.8 NR
7.6 0 0 NR
5.5 1.4 0 NR
13.3 1.2 NR NR
7.7 2.7 1.6 NR
54.2 43.9 43 4.4
29.4 13.7 11.8 1
3.2 1 1 NR
56.1 46.5 46.3 NR
13.8 5.8 5 NR
13.2 2.2 1.5 NR
26 12 9.7 NR
3.6 1.8 1.3 NR
5.2 0.9 6.5 NR
55.2 32.8 32.8 NR
8.4 0.6 0.6 NR
12.0 1.1 3.3 NR
Figure 2 TB case notification rate in Ethiopia, 1999–2012. Source: WHO report 2013 global TB control.
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http://www.aricjournal.com/content/3/1/311998 and 247 in 2012 and its highest TB case detection
rate and TB treatment success rate was observed in 2011.
Likewise, TB case notifications also increased over the
years and reached their highest level in 2011. The reason
for the increased number of notified cases might be due
to the expansion of health care services in the country.
The appearance and spread of drug-resistant TB strains in
new and previously treated cases worsens the TB problem
in Ethiopia [2]. In Ethiopia, a total of 1144 MDR-TB cases
were reported between 2007 and 2012 [1,9]. After falling
from 145 to 130 in 2008, it rose to 284 in 2012, indicating
a proportional increase of MDR-TB with time. According
to our review, the proportion of MDR-TB among all
TB cases varies from place to place [12-30]. In a study
conducted in the capital of the country, Addis Ababa
reported 12% MDR-TB cases [13]. Agonafir et al. in
2010 reported 43% MDR-TB and 4.4% XDR-TB. Another
study in three sites of Bahir Dar (northwest Ethiopia)
indicated 11.8% MDR-TB and 1% XDR-TB cases [20].
Additionally, 46.3% of MDR-TB was reported by Abate
et al. in 2012 and 9.7% by Ali et al. in the same yearFigure 3 Case detection rate of TB in Ethiopia, 1999–2012. Source: WHamong all cases. Another report on northwest Ethiopia
showed a higher rate at 5% of MDR-TB patients [23].
Studies in other parts of the country indicated 1.3%,
6.5% and 3.3% of MDR-TB [26,27,30]. Ejigu et al. in 2008
[28] and Hirpa et al. in 2013 [31] reported 32.8% and 134
MDR-TB cases, respectively. Reports in other countries
were consistent with this overall trend [1,8,9,18]. MDR-TB
and XDR-TB incidence in all of the reported studies
indicate the spread of MDR-TB and XDR-TB strains and
that the local control measures for the prevention of this
deadly disease are unsatisfactory. This suggests that estab-
lishing diagnostic facilities for early case detection and
treatment of MDR-TB in the country is significant.
Risk factors
The review indicated that previous exposure to TB treat-
ment was found to be the most significant risk factor
reported in Ethiopia [19,22,23,27,31,32,33]. Similar find-
ings were reported from studies conducted in Europe,
India, China, Portugal, Iran, Spain and east Africa [34-41].
In contrast to this report Biadglegne et al. in 2013 [26]O report 2013 global TB control.
Figure 4 Treatment success rate of TB in Ethiopia, 1999–2012. Source: WHO report 2013 global TB control.
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Ethiopia. Yimer et al. in 2011 [21] and Abebe et al. in
2012 [24] reported HIV to be a risk factor for MDR-TB.
However, a positive association between HIV and MDR-
TB has not been reported from study results in east Africa
and Ethiopia [22,23,31,33,41]. According to the Federal
Ministry of Health in Ethiopia [32], exposure to a known
MDR-TB case, history of using poor quality TB drugs,
treatment in a poorly-performing control program and
mal-absorption were found to have a positive association
with MDR-TB in Ethiopia. A case control study in Addis
Ababa, Ethiopia by Hirpa et al. in 2013 [31] reported drug
side effects during treatment (OR., 4.5, 95% CI., 1.9-10.5),
treatment not directly observed by a health worker (OR.,
11.7%., 95% CI., 4-34.3), interruption of treatment of at
least a day (OR., 13.1., 95% CI., 3.0-56.6), duration of treat-
ment between 2 and 7 months (OR., 14.8., 95% CI., 2.3-
96.4), and treatment with a category II regimen (p = 0.000)
as risk factors for MDR-TB. Being male has been reported
to be a risk factor for MDR-TB [22,26]. However, theseFigure 5 Proportion of MDR-TB in Ethiopia, 2007–2012. Source: WHOreports contradict the reports for other studies in the
county [19,22,23,27,31,33]. The design of the studies, fac-
tors such as sample size, education, place, study subjects
and other factors might be reasons for the discrepancies in
determining the risk factors associated to MDR-TB.
The WHO report in 2013 also confirmed that the
highest prevalence of MDR-TB among new and previ-
ously treated TB cases was 3.6% and 20.2%, respectively,
which is more than 17 times higher in previously treated
patients. In contrast to the results of this review, Antunes
et al. in 2000 [37] reported that social factors such as drug
abuse, poverty, and homelessness induces treatment fail-
ure and facilitates the emergence of MDR-TB. Alcoholism
and diabetes were also reported from Spain as important
predictors of MDR-TB [42]. Overall, previous exposure
to TB treatment was found to be the most frequently
reported factor of increased risk of MDR-TB in Ethiopia.
The high association of previous TB treatment to MDR-TB
might be explained due to inappropriate chemotherapy reg-
imens, inadequate or irregular drug supply, unsatisfactoryreport 2013 global TB control.
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Figure 6 Risk factors associated to the occurrence of MDR-TB in Ethiopia [19,21-24,27,31-33]. Adapted from Ref. No. 7.
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treatment and absence of infection control measures in
hospitals [37].
TB treatment regimens
Chemotherapy regimens that are used for the treatment
of all types of TB are classified as first- and second-line
anti-TB drugs [1]. First-line anti-TB drugs include isoniazid
(INH), rifampicin (RMP), pyrazinamide (PZA), ethambutol
(EMB) and streptomycin (STM). INH and RMP are the
two most commonly used drugs for treatment of TB.
First-line anti-TB drugs are safe and effective if used
correctly [1]. The effective treatment of MDR-TB is
critical to reducing the spread of drug-resistant TB in
the community. Drug groups for the treatment of
MDR-TB and XDR-TB treatment regimens have been
reviewed recently [43] and will not be covered here.
Currently, TB care and treatment has become more
complicated due to the emergence of M/XDR-TB.
Second-line drugs that are used for the treatment of
MDR-TB are listed as aminoglycosides; e.g., amikacin (Am)
and Kanamycin (Km); polypeptides: e.g., capreomycin
(Cm), viomycin and enviomycin; fluoroquinolones; e.g.,
ciprofloxacin (Cip), levofloxacin (Lfx), ofloxacin (Ofx),moxifloxacin (Mxf) and gatifloxacin; and thioamides: e.g.,
ethionamide (Eto), prothionamide and cycloserine (Cs),
and P-aminosalicylicacid (PAS) [1]. Second-line anti-TB
drugs are less potent, need to be administered for a much
longer time, are more toxic and are high-cost compared
to first-line anti-TB drugs [43]. Agents with unclear roles in
drug-resistant TB treatment are called third-line anti-TB
drugs such as clofazimine (Cfz), linezolid (Lzd), amoxicil-
lin/clavulanate (Amx/Clv), thioacetazone (Thz), imipenem/
cilastatin (Ipm/Cln) and high-dose isoniazid [1].
MDR-TB treatment regimens in Ethiopia
Obviously, the treatment of MDR-TB requires a longer
duration, is considerably more complicated, expensive and
toxic [1]. The longer treatment course of MDR-TB results
in poor treatment outcome, leading to the emergence of
XDR-TB. XDR-TB treatment is much more difficult
and costly and will stress national health budgets even
more than MDR-TB treatment [4]. The first patients were
admitted for MDR-TB treatment in Ethiopia in 2009 in a
rehabilitated isolation ward in St. Peter’s Hospital in Addis
Ababa [3]. In the same year, 45 MDR-TB patients were
enrolled initially in the second phase at St. Peter’s
Hospital. However, there has been a rapid scale-up of
Table 2 Positive vs negative association of risk factors with MDR-TB in Ethiopia
Risk factor Positive association with drug resistance Negative association with drug resistance
Previous exposure to anti-TB treatment Agonafir et al. [19], Abate et al. [22],
Tessema et al. [23], Esmael et al. [27],
Hirpa et al. [31], Berhan et al. [33]
Biadglegne et al. [26]
1+ bacterial load Esmael et al. [27]
Drug side effects to first-line anti-TB drugs Hirpa et al. [31]
Treatment not directly observed by a health worker Hirpa et al. [31]
Interruption of treatment at least a day Hirpa et al. [31]
HIV/AIDS Yimer et al. [21], Abebe et al. [24] Abate et al. [22], Tessema et al. [23],
Hirpa et al. [31], Berhan et al. [33]
Age Yimer et al. [21], Abate et al. [22],
Tessema et al. [23], Esmael et al. [27],
Hirpa et al. [31], Berhan et al. [33]
Being male Biadglegne et al. [26] Yimer et al. [21], Abate et al. [22],
Tessema et al. [23], Esmael et al. [27],
Hirpa et al. [31],
Newly treated cases Biadglegne et al. [26] Agonafir et al. [19], Abate et al. [22],
Tessema et al. [23], Esmael et al. [27],
Hirpa et al. [31], Berhan et al. [33]
Treatment in poorly performing control program FMOH [32]
Exposure to a known MDR-TB case FMOH [32]
History of using poor quality of drugs FMOH [32]
Mal-absorption FMOH [32]
Failure of first-line short-course chemotherapy FMOH [32]
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the national and regional state level, there were 19 care
sites for drug-resistant cases and therapy was initiated
on 811 patients in 2012. Of these nine of them were
XDR-TB. Progress is being made; however, the response
is too slow given the prevalence MDR-TB in Ethiopia.
This is because the expanding access to care for MDR-
TB cases is limited to the main and regional large cities.
As a result of this, MDR-TB patients in rural and remote
areas may not have access to health care services, may
prefer consultation with traditional healers that are more
readily available and come late to health care centers
(personal communications). Delayed case detection and
treatment of MDR-TB cases might also contribute to
the spread of the disease in the community [32]. Thus,
there is a need to train health extension workers and
volunteers how to screen and care for MDR-TB cases at
the community level. Continuous public health awareness
about MDR-TB at the community level is also very
important to reduce the spread of this deadly disease.
The facilities that are equipped to treat MDR-TB are
supported by the Ministry of Health and non-governmental
organizations (NGOs). The treatment policy for MDR-TB
in Ethiopia combines standardized and individualized
treatment based on second-line drug susceptibility testing
[3]. A standard regimen is given to all MDR-confirmed
cases daily under direct observation by a health careworker at a health care centre and by family DOTS
supporter (s) at home [3]. Furthermore, continuous moni-
toring and building capacity for family DOTS supporters
are essential components of the DOTS strategy. The
regimens include at least four drugs that are certain or
expected to be effective and the duration is a minimum
of 18 months after culture conversion [3]. The purpose
of effective treatment of drug susceptible TB is curing
the patient, interrupting transmission of TB to other
persons, and preventing the development of drug resistant
strains [1]. These goals are not being achieved in many
regions of the country though anti-tuberculosis drugs
are available. This might be due to either patient non-
adherence to treatment or clinicians’ non-adherence to
the national treatment guidelines or both [44].
Mechanisms of drug resistance in M.tuberculosis
Understanding the mechanism of drug resistance to anti-
TB drugs not only helps to put measures into practice to
limit the spread of such resistance but also enables us to
recognize genes linked with drug resistance [7]. Most
chromosomal mutations in the genome of M.tuberculosis
that confer resistance to anti-TB drugs occurred spontan-
eously [45]. Data from the Johnson et al. report in 2006
showed the rate of spontaneous mutation for INH and
RMP is 3.4×10−6 and 3.1×10−8, respectively. However, the
amplification of the above mentioned genetic mutation
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ance to first- and second-line drugs have been reviewed
recently [7,45] and will not be reviewed here.
Diagnosis of drug-resistant TB
Laboratory investigations are a vital part of the clinical
assessment and guide the selection of drugs for patient
management. One main element of the TB control strat-
egy is effective case management through early detection
and treatment of the patients [1], which is economically
beneficial since Ethiopia uses expensive drugs as first-
and second-line anti-TB treatment. Thus, laboratory
availability for performing drug resistance testing is
crucial, since diagnosis of drug-resistant TB usually
requires pure culture of M. tuberculosis. MDR-TB is a
particularly threatening infection that is difficult to
diagnose without a proper laboratory facility. The most
critical factor in addressing MDR-TB in Ethiopia is the
lack of laboratory infrastructure and transport networks
that can provide rapid diagnosis. In addition, transmis-
sion dynamics of MDR-TB in Ethiopia are not well
understood. In fact, laboratory services in Ethiopia
remain in a stage of fine needle aspiration cytology
(FNAC) and Ziehl Nielsen (ZN) smear in clinical specimens
[46]. FNAC and ZN smear lack sensitivity and specificity.
Moreover, these methods are limited due to lack of species
identification and drug susceptibility testing. Culture-based
drug susceptibility testing methods can provide definitive
results, but are labor intensive, time consuming [47] and
generally unavailable in resource-limited settings where TB
is endemic. For instance in Ethiopia, drug susceptibility
tests for Mycobacterium species are not available as routine
tests, not even for patients with suspected infection by
drug resistant strains. So far, there are two laboratories
in the capital city Addis Ababa that perform molecular
(LPA) and conventional drug susceptibility tests. Due to
this problem, empiric treatment for MDR-TB suspects
is common, resulting in problematic treatment outcomes
of MDR-TB cases.
Molecular methods such as real-time polymerase chain
reaction (RT-PCR), solid phase hybridization assays and
sequencing that target drug resistance mutations are
suitable approaches for rapid drug susceptibility testing
[48]. Line probe assays (LPAs) such as Genotype MTBDR,
the new GenoType MTBDRplus and GenoType MTBDRsl
assay (Hain Life Science GmbH, Nehren, Germany) have
also been described for detection of MTBC-specific DNA
and gene mutation linked with drug resistance from clinical
specimens and culture isolates [23,26,40,48-50]. The Geno-
Type MTBDRplus assay detects the resistance to both INH
and RMP simultaneously and thus can detect MDR-TB
[23,26]. The GenoType MTBDRsl assay for detection of
MTBC resistant to second-line drugs was reported on
recently [23]. A real-time PCR based approach, XpertMTB/RIF assay (Cepheid, Sunnyvale, CA) and a reverse
hybridization-based line probe assay, the INNO-LiPA
Rif. TB (LiPA) (inogenetics, Ghent, Belgium), have been
endorsed by the WHO to rapidly identify M.tuberculosis
and associated mutations to RMP resistance. The sensitivity
and specificity of molecular techniques compared to con-
ventional methods of drug resistance testing was reported
[23,26,49-55]. In recent years the microscopic observation
drug susceptibility (MODS) assay was introduced for de-
tecting drug resistant M. tuberculosis from liquid media
[56,57]. Resistance is detected by the presence of anti-
tuberculosis drugs and it returns results within seven days
[56]. The sensitivity to detect MDR-TB compared to con-
ventional drug susceptibility tests was reported [56,57].
Control of MDR-TB in Ethiopia
Infection control is a key element to prevent transmission
of MDR-TB. Administrative, environmental and personal
respiratory protection measures are key interventions [3].
Good administrative control is the most important in
infection control of MDR-TB. In particular, environmental
controls and personal respiratory protection measures will
not work in the absence of good administrative control
measures [3]. These measures must be ensured in all
health facilities involved in MDR-TB care in Ethiopia.
Effective treatment, control and prevention of emergence
and transmission of drug-resistant TB at the community
level are required to reduce the increasing trend in MDR-
TB in Ethiopia [32]. Environmental control measures
should never replace administrative controls; however, they
are intended to reduce the concentration of infectious
droplet nuclei in the air. Such measures include maxi-
mizing natural ventilation and controlling the direction
of airflow [3]. Opening windows to increase natural
ventilation and the use of fans to control the direction of
airflow is crucial to reduce infection in resource-limited
settings. Personal respiratory protection protects health-
care workers and other people from being infected [1].
The national guideline for control of drug-resistant TB
is understood and, theoretically, should be effortless to
implement in the country. In contradiction, however,
the prevalence of MDR-TB is often increasing in Ethiopia.
Clearly a directly observed treatment, short-course (DOTS)
strategy for patients is the best weapon against MDR-TB
[58] and it comprises political commitment with increased
and sustained budgeting, a standardized treatment regimen
directly observed by a health care worker, an effective
drug supply and management system, case detection
through quality assured laboratories, and a monitoring
and evaluation system with TB infection control impact
measures. The strategy also includes measures to address
TB infection control advocacy and to support operational
research [58]. The enhanced DOTS program, DOTS-plus
has been developed for managing MDR-TB in resource-
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investment in facilities for culture and drug susceptibility
testing for the detection of drug-resistant TB and provision
of appropriate second-line drugs [59].Conclusion
This review indicated that MDR-TB in Ethiopia is a
serious public health problem that needs to be addressed
urgently. Several reports indicated that previous exposure
of anti-TB treatment increased the risk of MDR-TB in
Ethiopia. Thus, strengthening early case detection and
proper treatment of drug susceptible TB according to
WHO treatment guidelines to ensure adequate treatment
success rates is essential. This will limit the emergence
of M/XDR-TB and prevent the spread of the disease.
Consequently, a rapid build-up of MDR-TB diagnosis and
treatment sites for the implementation of the DOTS-plus
strategy is critical to interrupt transmission of this deadly
disease in the country.
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